pentobarbital will decrease the level or outcome of conjugated estrogens by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will lessen the level or effect of meloxicam by influencing hepatic enzyme CYP2C9/10 metabolism. Slight/Significance Unidentified.
pentobarbital will lower the extent or outcome of quinine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unidentified.
pentobarbital will minimize the extent or impact of lumefantrine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with strong CYP3A4 inducers can lead to reduced serum concentrations and loss of antimalarial efficacy
pentobarbital will lessen the extent or impact of isradipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Mysterious.
pentobarbital will lower the level or effect of darunavir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
Contraindicated (one)pentobarbital will decrease the extent or result of lumefantrine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with sturdy CYP3A4 inducers may lead to lowered serum concentrations and loss of antimalarial efficacy
pentobarbital will lessen the extent or impact of methadone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
Should the dose with the concomitant CYP3A4 inducer can't be decreased or discontinued, implant removal might be essential and the client must then be handled with a buprenorphine dosage kind that permits dose adjustments. If a CYP3A4 inducer is discontinued in a client who continues to be stabilized on buprenorphine, monitor check here the patient for overmedication.
pentobarbital will lessen the extent or outcome of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
In case the buprenorphine dose is inadequate and also the CYP3A4 inducer can not be minimized or discontinued, transition the patient back again into a buprenorphine formulation that permits dose changes.
pentobarbital will minimize the extent or outcome of norgestrel by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Closely. Moderate CYP3A4 inducers might reduce progestin concentration; take into account usage of additional barrier solutions
pentobarbital will lower the extent or outcome of propafenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unknown.
pentobarbital will lessen the level or influence of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.